PHP
MYOV

Parkman Healthcare Partners’s Myovant Sciences Ltd. MYOV Stock Holding History

Parkman Healthcare Partners’s Portfolio MYOV Stock Details MYOV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-99,413
Closed -$1.54M – 80
2019
Q4 		$1.54M Buy
+99,413
New +$1M 0.45% 57

Other funds holding MYOV

Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NCM
NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Parkman Healthcare Partners's MYOV Position: Q1 2020 in Review

Parkman Healthcare Partners sold out of Myovant Sciences Ltd. (MYOV) in Q1 2020, closing a stake of 99,413 shares — an estimated $1.54M sold.

Parkman Healthcare Partners first reported a position in MYOV in Q4 2019 and held it in 1 quarter. The position peaked at $1.54M in Q4 2019. 75 funds tracked by Wall St. Rank hold MYOV as of Q1 2020.

  • Parkman Healthcare Partners reported no remaining Myovant Sciences Ltd. position as of Q1 2020 after selling out during the quarter.
  • Parkman Healthcare Partners sold 99,413 Myovant Sciences Ltd. shares in Q1 2020, an estimated $1.54M.
  • Parkman Healthcare Partners first reported a position in Myovant Sciences Ltd. in Q4 2019 and held it in 1 quarter.
  • Parkman Healthcare Partners's Myovant Sciences Ltd. position peaked at $1.54M in Q4 2019.
  • 75 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q1 2020.

Based on Parkman Healthcare Partners's 13F filing for Q1 2020, filed 15 May 2020.